Skip to main content
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. logo

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. — Investor Relations & Filings

Ticker · 301096 ISIN · CNE1000056N5 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 513 across all filing types
Latest filing 2026-05-24 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301096

About Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.

https://www.hzbio-s.com

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. provides integrated research, development, and manufacturing services for drug product development. The company specializes in formulation technology, analytical chemistry, and process optimization for chemical drugs. Its service portfolio encompasses pre-formulation studies, dosage form design, stability testing, and clinical trial material production. Bio-Sincerity supports the development of both generic medications and innovative small molecule therapeutics, offering technical expertise in complex delivery systems and regulatory submission documentation. By leveraging advanced laboratory facilities and pilot production capabilities, the organization facilitates the transition of drug candidates from laboratory scale to commercial manufacturing, focusing on technical precision and quality management systems.

Recent filings

Filing Released Lang Actions
关于筹划控制权变更事项停牌公告
Regulatory Filings Classification · 83% confidence The document is a Chinese securities announcement about the suspension of trading due to the planning of a major control change by the company’s controlling shareholders. It is not an actual financial report or formal merger agreement, but a regulatory notice required under exchange listing rules (a suspension announcement). There is no detailed merger proposal, financial statements, or executive management changes. It therefore falls under General Regulatory Filings (RNS) as a miscellaneous regulatory announcement.
2026-05-24 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is an announcement of the 2025 annual shareholders meeting resolutions, detailing the meeting logistics, attendance figures, and voting results on various proposals. It is not the meeting materials or full report, but the formal declaration of voting outcomes. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-15 Chinese
北京炜衡（杭州）律师事务所关于杭州百诚医药科技股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 91% confidence The document is a law firm’s legal opinion (法律意见书) on the legality of convening and conducting the 2025 Annual General Meeting, including procedural review and vote tallies. It is an attestation/certification letter rather than the AGM materials themselves or a pure vote‐result announcement. Under the “certification rule,” such legal opinion letters are classified as a general Regulatory Filing (RNS) rather than AGM information or DVA.
2026-05-15 Chinese
非经营性资金占用及其他关联资金往来情况的专项审计说明
Audit Report / Information Classification · 95% confidence The document is a specialized audit report focusing on non-operating fund occupation and other related party fund transactions for the fiscal year 2025. It includes an auditor's opinion, references to regulatory guidelines, and detailed financial tables related to these transactions. The document is titled as a 'special audit explanation' and contains an audit conclusion, indicating it is a standalone audit report rather than a full annual report or a simple announcement. The length is under 5,000 characters but contains substantive audit content and financial data, not just a notice or certification. Therefore, it fits the category of an Audit Report / Information (AR).
2026-04-23 Chinese
董事会对独立董事独立性自查情况的专项报告
Regulatory Filings Classification · 95% confidence The document is a special report from the board of directors assessing the independence of the company's independent directors, referencing regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange listing rules. It is a compliance-related report on governance matters, specifically about independent director independence. The document is very short (414 characters) and does not contain financial data or detailed financial statements. It is not an annual report, audit report, or financial filing. It is a governance-related disclosure but does not fit the detailed governance report category (CGR) which usually involves internal rules or board structure. Instead, it is a regulatory compliance filing related to governance. Given the short length and nature, it fits best under Regulatory Filings (RNS) as a general compliance announcement that does not fit other categories.
2026-04-23 Chinese
独立董事2025年度述职报告（黄志雄）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2025 Annual Work Report" for Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. It details the independent director's activities, attendance at board and shareholder meetings, committee participation, supervision of financial and internal control matters, and evaluation of company governance and compliance during the 2025 fiscal year. The content focuses on the director's duties, oversight, and opinions rather than presenting financial statements or audit results. It is a formal report on the independent director's annual performance and governance role, not a financial report, audit report, or announcement of voting results. This type of document fits best under Board/Management Information (MANG), as it relates to board member duties and governance activities.
2026-04-23 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.